Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up

V. Kolek, I. Grygárková, L. Koubková, J. Skřičková, J. Švecová, D. Sixtová, J. Bartoš, A. Tichopád,

. 2017 ; 12 (7) : e0181803. [pub] 20170721

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030675

Grantová podpora
NV16-32318A MZ0 CEP - Centrální evidence projektů

OBJECTIVES: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions. MATERIAL AND METHODS: A prospective, single-arm, multicenter, non-interventional study evaluated the tolerability, dose intensity and survival resulting from adjuvant use of intravenous carboplatin (AUC 5 on day 1) with vinorelbine administered both intravenously (25 mg/m2 on day 1) and orally (60 mg/m2 on day 8) within four cycles of 21 days each. A total of 74 patients with a median age of 64 years were observed. RESULTS: The mean number of accomplished cycles was 3.78, and 62 patients (83.7%) completed all four planned cycles. Relative dose intensity for carboplatin was 88.9%, for intravenous vinorelbine 93.1%, and for oral vinorelbine 83.2%. Median follow-up was 4.73 years. Median disease-specific survival (DSS) was 7.63 years, median overall survival (OS) was 5.90 years, median disease-free survival (DFS0) was 4.43 years, and five-year survival was 56.2%. TNM stage of disease significantly affected DSS and OS. Favorable survival was observed in females, nonsmokers, patients aged over 65 years, patient with prior lobectomy, patients with tumor of squamous histology, and those who finished the planned therapy, but the differences were non-significant. CONCLUSION: Adjuvant carboplatin with vinorelbine switched from intravenous to oral administration was shown to be a favorable regimen with regard to tolerability and safety. Compliance to therapy was high, and survival parameters were promising, showing that applied regimen can be another potential option for adjuvant chemotherapy in patients with NSCLC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030675
003      
CZ-PrNML
005      
20171025122720.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0181803 $2 doi
035    __
$a (PubMed)28732018
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kolek, Vítězslav $u Department of Respiratory Medicine, University Hospital, Olomouc, Czech Republic.
245    10
$a Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up / $c V. Kolek, I. Grygárková, L. Koubková, J. Skřičková, J. Švecová, D. Sixtová, J. Bartoš, A. Tichopád,
520    9_
$a OBJECTIVES: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions. MATERIAL AND METHODS: A prospective, single-arm, multicenter, non-interventional study evaluated the tolerability, dose intensity and survival resulting from adjuvant use of intravenous carboplatin (AUC 5 on day 1) with vinorelbine administered both intravenously (25 mg/m2 on day 1) and orally (60 mg/m2 on day 8) within four cycles of 21 days each. A total of 74 patients with a median age of 64 years were observed. RESULTS: The mean number of accomplished cycles was 3.78, and 62 patients (83.7%) completed all four planned cycles. Relative dose intensity for carboplatin was 88.9%, for intravenous vinorelbine 93.1%, and for oral vinorelbine 83.2%. Median follow-up was 4.73 years. Median disease-specific survival (DSS) was 7.63 years, median overall survival (OS) was 5.90 years, median disease-free survival (DFS0) was 4.43 years, and five-year survival was 56.2%. TNM stage of disease significantly affected DSS and OS. Favorable survival was observed in females, nonsmokers, patients aged over 65 years, patient with prior lobectomy, patients with tumor of squamous histology, and those who finished the planned therapy, but the differences were non-significant. CONCLUSION: Adjuvant carboplatin with vinorelbine switched from intravenous to oral administration was shown to be a favorable regimen with regard to tolerability and safety. Compliance to therapy was high, and survival parameters were promising, showing that applied regimen can be another potential option for adjuvant chemotherapy in patients with NSCLC.
650    _2
$a intravenózní podání $x metody $7 D061605
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a karboplatina $x aplikace a dávkování $7 D016190
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x mortalita $7 D002289
650    _2
$a adjuvantní chemoterapie $x metody $7 D017024
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x mortalita $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a vinblastin $x aplikace a dávkování $x analogy a deriváty $7 D014747
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Grygárková, Ivona $u Department of Respiratory Medicine, University Hospital, Olomouc, Czech Republic.
700    1_
$a Koubková, Leona $u Department of Pneumology, University Hospital, Praha-Motol, Czech Republic.
700    1_
$a Skřičková, Jana $u Department of Respiratory Diseases and Tuberculosis, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Švecová, Jiřina $u Department of Oncology, Hospital Tabor, Tabor, Czech Republic.
700    1_
$a Sixtová, Dimka $u Department of Respiratory Diseases, Memorial Thomayer Hospital, Praha, Czech Republic.
700    1_
$a Bartoš, Jiří $u Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic.
700    1_
$a Tichopád, Aleš $u Kantar Health s.r.o., Praha, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 7 (2017), s. e0181803
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28732018 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122802 $b ABA008
999    __
$a ok $b bmc $g 1254268 $s 991702
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 7 $d e0181803 $e 20170721 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV16-32318A $p MZ0
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace